Literature DB >> 34861400

Endoderm and mesoderm derivatives in embryonic stem cell differentiation and their use in developmental toxicity testing.

R H Mennen1, M M Oldenburger2, A H Piersma3.   

Abstract

Embryonic stem cell differentiation models have increasingly been applied in non-animal test systems for developmental toxicity. After the initial focus on cardiac differentiation, attention has also included an array of neuro-ectodermal differentiation routes. Alternative differentiation routes in the mesodermal and endodermal germ lines have received less attention. This review provides an inventory of achievements in the latter areas of embryonic stem cell differentiation, with a view to possibilities for their use in non-animal test systems in developmental toxicology. This includes murine and human stem cell differentiation models, and also gains information from the field of stem cell use in regenerative medicine. Endodermal stem cell derivatives produced in vitro include hepatocytes, pancreatic cells, lung epithelium, and intestinal epithelium, and mesodermal derivatives include cardiac muscle, osteogenic, vascular and hemopoietic cells. This inventory provides an overview of studies on the different cell types together with biomarkers and culture conditions that stimulate these differentiation routes from embryonic stem cells. These models may be used to expand the spectrum of embryonic stem cell based new approach methodologies in non-animal developmental toxicity testing.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Differentiation routes; Endoderm; Mesoderm; Pluripotent stem cells

Mesh:

Year:  2021        PMID: 34861400     DOI: 10.1016/j.reprotox.2021.11.009

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  1 in total

Review 1.  Toward better assessments of developmental toxicity using stem cell-based in vitro embryogenesis models.

Authors:  Yusuke Marikawa
Journal:  Birth Defects Res       Date:  2022-01-31       Impact factor: 2.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.